Viking Therapeutics, Inc. (VKTX) earnings date
Feb 10, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 28 days, typically, give or take 7 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Oct 28, 2026 | after close | 28 | 8-K |
| Q2 FY2026 | Wed, Jul 29, 2026 | after close | 29 | 8-K |
| Q1 FY2026 | Wed, Apr 29, 2026 | after close | 29 | 8-K |
| Q4 FY2025 | Wed, Feb 11, 2026 | after close | 42 | 8-K |
| Q3 FY2025 | Wed, Oct 22, 2025 | after close | 22 | 8-K |
| Q2 FY2025 | Wed, Jul 23, 2025 | after close | 23 | 8-K |
| Q1 FY2025 | Wed, Apr 23, 2025 | after close | 23 | 8-K |
| Q4 FY2024 | Wed, Feb 5, 2025 | after close | 36 | 8-K |
What they guided beta
| Q3 FY2026 | "Upon completion, we expect to initiate a 28-day multiple ascending dose study of VK3019 in the first quarter of 2027." exhibit |
| Q3 FY2026 | "The company expects these studies to be completed in 2027." exhibit |
| Q3 FY2026 | "The company anticipates the results of the extension studies to be available in 2028." exhibit |
| Q3 FY2026 | "Importantly, results from this study will help inform the selection of doses in the upcoming VANQUISH extension studies, expected to begin in early 2027." exhibit |
| Q3 FY2026 | "The company expects the results from Part 2 of this study to be available in 2027." exhibit |
| Q2 FY2026 | "Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- -- Phase 1 Study of Amylin Agonist VK3019 Underway -- -- Strong Quarter-End Cash Position of $502 Million --" exhibit |
| Q2 FY2026 | "During the period, the company continued to prepare for initiation of Phase 3 trials with the oral formulation of VK2735, expected to begin in the fourth quarter of this year." exhibit |
| Q2 FY2026 | "To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until August 5, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference ID # 7609005 ." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/VKTX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/VKTX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/VKTX/"><img src="https://veritasdata.dev/embed/VKTX.svg" alt="VKTX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/VKTX/)
Script
<script async src="https://veritasdata.dev/embed/VKTX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/VKTX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.